Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN, Estey E, Raad I, Giles F, Cortes J, Shen Y, Kontoyiannis D, Koller C, Munsell M, Beran M, Kantarjian H. Mattiuzzi GN, et al. Among authors: koller c. Cancer. 2003 Jan 15;97(2):450-6. doi: 10.1002/cncr.11094. Cancer. 2003. PMID: 12518369 Free article. Clinical Trial.
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O'Brien S, Keating M, Estey E. Cortes J, et al. Among authors: koller c. Cancer. 2003 Mar 1;97(5):1234-41. doi: 10.1002/cncr.11180. Cancer. 2003. PMID: 12599230 Free article. Clinical Trial.
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Giles F, Thomas D, Garcia-Manero G, Faderl S, Cortes J, Verstovsek S, Ferrajoli A, Jeha S, Beran M, Koller C, Andreeff M, Cahill A, Clairmont C, Sznol M, Kantarjian H. Giles F, et al. Among authors: koller c. Clin Cancer Res. 2004 May 1;10(9):2908-17. doi: 10.1158/1078-0432.ccr-03-0738. Clin Cancer Res. 2004. PMID: 15131024 Clinical Trial.
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J, Kantarjian H. Cortes J, et al. Among authors: koller c. Clin Cancer Res. 2004 May 15;10(10):3371-6. doi: 10.1158/1078-0432.CCR-03-0508. Clin Cancer Res. 2004. PMID: 15161691 Clinical Trial.
321 results